Skip to main content

Table 2 Clinical and pathological features of urine samples from asymptomatic controls and prostate cancer patients enrolled in this study (cohort #2)

From: Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients

  Urine (cohort #2)
Clinicopathological data AC PCa
Patients, n 32 87
Median age, years (range) 58 (50–64) 64 (47–75)
Median PSA (ng/mL) (range) n.a. 8.80 (3.50–20.40)
Pathological stage, n (%)
 pT2 n.a. 43 (49.43)
 pT3a n.a. 35 (40.23)
 pT3b n.a. 9 (10.34)
Prognostic grade group, n (%)
 1 n.a. 34 (39.08)
 2 n.a. 39 (44.83)
 3 n.a. 7 (8.05)
 4 n.a. 5 (5.75)
 5 n.a. 2 (2.30)
  1. AC asymptomatic controls, PCa prostate cancer, n.a not applicable